{
    "organizations": [],
    "uuid": "e0ed911c6c8bdbac8f9c3345938a3502acff3ac3",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-hemispherx-expands-ampligen-early/brief-hemispherx-expands-ampligen-early-access-programme-to-canada-to-treat-me-cfs-patients-idUSFWN1RH0GQ",
    "ord_in_thread": 0,
    "title": "BRIEF-Hemispherx Expands Ampligen Early Access Programme To Canada To Treat ME/CFS Patients",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 4 (Reuters) - Hemispherx Biopharma Inc:\n* HEMISPHERX EXPANDS AMPLIGEN EARLY ACCESS PROGRAMME TO CANADA TO TREAT ME/CFS PATIENTS\n* ‍AMENDED TO INCLUDE MANAGEMENT OF A SAP IN CANADA FOR PATIENTS SUFFERING FROM MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME​\n* ‍FIRST COMMERCIAL SIZE BATCH OF AMPLIGEN, WHICH WILL CONTAIN ABOUT 8,300 VIALS, IS ANTICIPATED TO BE AVAILABLE IN MAY​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-04T20:37:00.000+03:00",
    "crawled": "2018-04-05T17:06:50.022+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "hemispherx",
        "biopharma",
        "inc",
        "hemispherx",
        "expands",
        "ampligen",
        "early",
        "access",
        "programme",
        "canada",
        "treat",
        "patient",
        "include",
        "management",
        "sap",
        "canada",
        "patient",
        "suffering",
        "myalgic",
        "fatigue",
        "commercial",
        "size",
        "batch",
        "ampligen",
        "contain",
        "vial",
        "anticipated",
        "available",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}